Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection

Vaccine.

Uziel Y, Moshe V, Onozo B, Kulcsár A, Tróbert-Sipos D, Akikusa JD, Salviato Pileggi G, Maritsi D, Kasapcopur O, Rodrigues M, Smerla R, Rigante D, Makay B, Atsali E, Wulffraat N, Toplak N, PReS working party of Vaccination Study Group.

doi: 10.1016/j.vaccine.2020.01.037.

Autoimmune Disease

Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis

Autoimmun Rev.

Bragazzi NL, McGonagle D, Watad S, Adawi M, Mahroum N, Damiani G, Conic R, Bridgewood C, Mahagna H, Giacomelli L, Eggenhöffner R, Mahamid M, Pigatto PDM, Amital H, Watad A

doi: 10.1016/j.autrev.2018.08.002.

Melanoma and Skin Cancer

Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases

Ann Surg Oncol.

Faries MB, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, DeConti RC, Lee JE, Huth JF, Wagner J, Dalgleish A, Pertschuk D, Nardo C, Stern S, Elashoff R, Gammon G, Morton DL; MMAIT-IV Clinical Trial Group

doi: 10.1245/s10434-017-6072-3.

Psoriatic ArthritisRheumatoid ArthritisSpinal Disorders

Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study

Rheumatology (Oxford).

Bühler S, Jaeger VK, Adler S, Bannert B, Brümmerhoff C, Ciurea A, Distler O, Franz J, Gabay C, Hagenbuch N, Herzog C, Hasler P, Kling K, Kyburz D, Müller R, Nissen MJ, Siegrist CA, Villiger PM, Walker UA, Hatz C

doi: 10.1093/rheumatology/kez045.

Further Publications Dermatology

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Lancet

Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ, Oxford COVID Vaccine Trial Group.

doi: 10.1016/S0140-6736(20)32466-1

Rheumatoid Arthritis

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial

Arthritis Res Ther

Fleischmann RM, Alvarez DF, Bock AE, Cronenberger C, Vranic I, Zhang W, Alten R

doi: 10.1186/s13075-021-02626-4

Immunotherapy

Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations

Hum Vaccin Immunother.

Gatti-Mays ME, Redman JM, Collins JM, Bilusic M

doi: 10.1080/21645515.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial

Ann Rheum Dis.

Ozen S, Ben-Cherit E, Foeldvari I, Amarilyo G, Ozdogan H, Vanderschueren S, Marzan K, Kahlenberg JM, Dekker E, De Benedetti F, Koné-Paut I

doi: 10.1136/annrheumdis-2020-217419.

T cell Receptor Alpha Variable 12-2 bias in the immunodominant response to Yellow fever virus

Eur J Immunol.

Bovay A, Zoete V, Dolton G, Bulek AM, Cole DK, Rizkallah PJ, Fuller A, Beck K, Michielin O, Speiser DE, Sewell AK, Fuertes Marraco SA

doi: 10.1002/eji.201747082.

Related content